Par Sues FDA To Get "Tailored" Rules On Off-Label Promotion
This article was originally published in The Pink Sheet Daily
Executive Summary
Par claims it is being blocked from informing physicians about the approved use of Megace ES; the case could be derailed by a DoJ complaint against Par, as was Allergan's suit against FDA.